Rhythm Pharmaceuticals, Inc. (RYTM) stock
RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30249% above fair value
$109.86−2.30 (-2.05%)
Close on Nov 12, 2026Market cap $7.56BP/E –Yield –
Rhythm Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Rhythm Pharmaceuticals's gross margin for the twelve months ending Jun 30, 2026 was 89.0%. For fiscal 2025 it was 89.7%, against 89.7% the year before. The highest annual figure on record is 91.0% in fiscal 2022.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 89.7% | +0.0 |
| FY2024 | Dec 31, 2024 | 89.7% | +1.7 |
| FY2023 | Dec 31, 2023 | 88.0% | −3.0 |
| FY2022 | Dec 31, 2022 | 91.0% | +10.0 |
| FY2021 | Dec 31, 2021 | 81.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 87.5% | −1.1 |
| Q1 FY2026 | Mar 31, 2026 | 88.1% | −0.8 |
| Q4 FY2025 | Dec 31, 2025 | 91.6% | +0.7 |
| Q3 FY2025 | Sep 30, 2025 | 89.3% | +0.8 |
| Q2 FY2025 | Jun 30, 2025 | 88.6% | −1.3 |
| Q1 FY2025 | Mar 31, 2025 | 88.8% | −0.3 |
| Q4 FY2024 | Dec 31, 2024 | 90.9% | +4.3 |
| Q3 FY2024 | Sep 30, 2024 | 88.5% | −0.8 |
| Q2 FY2024 | Jun 30, 2024 | 89.9% | +1.5 |
| Q1 FY2024 | Mar 31, 2024 | 89.2% | +1.6 |
| Q4 FY2023 | Dec 31, 2023 | 86.7% | −1.6 |
| Q3 FY2023 | Sep 30, 2023 | 89.3% | +0.9 |
| Q2 FY2023 | Jun 30, 2023 | 88.4% | −7.5 |
| Q1 FY2023 | Mar 31, 2023 | 87.6% | +3.0 |
| Q4 FY2022 | Dec 31, 2022 | 88.3% | +1.3 |
| Q3 FY2022 | Sep 30, 2022 | 88.4% | +10.0 |
| Q2 FY2022 | Jun 30, 2022 | 95.8% | +45.8 |
| Q1 FY2022 | Mar 31, 2022 | 84.6% | −3.9 |
| Q4 FY2021 | Dec 31, 2021 | 87.0% | – |
| Q3 FY2021 | Sep 30, 2021 | 78.4% | – |
| Q2 FY2021 | Jun 30, 2021 | 50.0% | – |
| Q1 FY2021 | Mar 31, 2021 | 88.6% | – |
See a number that looks wrong?